MedTrace Logo

Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD

NCT06215144 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2026-01-15

No results posted yet for this study

Summary

To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD

Conditions

  • Attention-Deficit/Hyperactivity Disorder (ADHD)

Interventions

DRUG

NRCT-101SR

NRCT-101SR is a sustained release formulation.

Sponsors & Collaborators

  • Neurocentria, Inc.

    lead INDUSTRY

Principal Investigators

  • Guosong Liu, MD, PhD · Neurocentria, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-25
Primary Completion
2025-10-10
Completion
2025-11-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06215144 on ClinicalTrials.gov